Evidence map›Paper›PMID 32330116›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2019

Contribution of normal aging to brain atrophy in MS.

Christina J Azevedo, Steven Y Cen, Amir Jaberzadeh, Ling Zheng, Stephen L Hauser, Daniel Pelletier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Christina J AzevedoFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco.
Steven Y CenFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco.
Amir JaberzadehFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco.
Ling ZhengFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco.
Stephen L HauserFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco.
Daniel PelletierFrom the Department of Neurology (C.J.A., S.Y.C., A.J., L.Z., D.P.), University of Southern California, Los Angeles; and Department of Neurology (S.L.H.), University of California, San Francisco. Daniel.Pelletier@usc.edu.
University of Southern California · US

Funding

Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Molecular and Genetic Predictors of Disability Progression in MSR01NS062885 · NINDS · YALE UNIVERSITY · PI PELLETIER, DANIEL · 2009 to 2013
$1.6M
NCATS NIH HHS UL1 TR001855NINDS NIH HHS R01 NS062885
6 · The paper itself

Abstract

objectiveTo identify the top brain regions affected by MS-specific atrophy (i.e., atrophy in excess of normal aging) and to test whether normal aging and MS-specific atrophy increase or decrease in these regions with age.

methodsSix hundred fifty subjects (2,790 MRI time points) were analyzed: 520 subjects with relapse-onset MS from a 5-year prospective cohort with annual standardized 1-mm 3D T1-weighted images (3DT1s; 2,483 MRIs) and 130 healthy controls with longitudinal 3DT1s (307 MRIs). Rates of change in all FreeSurfer regions (v5.3) and Structural Image Evaluation Using Normalization of Atrophy (SIENA) were estimated with mixed-effects models. All FreeSurfer regions were ranked by the MS-specific atrophy slope/standard error ratio (β

resultsThe top-ranked regions were all gray matter structures. For SIENA, normal aging increased from 0.01%/y at age 30 years to -0.31%/y at age 60 years (-0.11% ± 0.032%/decade,

conclusionsFor SIENA and thalamic atrophy, the contribution of normal aging increases with age, but does not change in the putamen and caudate. This may have substantial implications to understand the biology of brain atrophy in MS.

Indexed as

AdultAgedAgingAtrophyBrain DiseasesCaudate NucleusFemaleGray MatterHumansMagnetic Resonance ImagingMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingProspective StudiesPutamenThalamus

Identifiers

PMID32330116
PMCPMC6807662
OpenAlexW2976387276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.